Matinas Biopharma Hl (MTNB) 0.6800 $MTNB Matinas

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Matinas Biopharma Hl (MTNB) 0.6800 $MTNB

Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
GlobeNewswire - Mon Jun 20, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data on its investigational drug, MAT2501 (orally-administered encochleated amikacin) for chronic and acute bacterial infections, including non-tuberculous mycobacteria (NTM) and multi-drug resistant gram-negative bacterial infections, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy (ASM Microbe/ICAAC 2016) scientific meeting being held June 16 - 20 in Boston, MA.

Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
- Study demonstrates higher potency and better safety/tolerability of ibuprofen in lipid-crystal nano-particle formulation -

Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 31, 6:05AM CDT
-- 2015 transformative year with focus on developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections

UPDATE -- OTCQX and OTCQB Companies to Present at 2016 Roth Conference
PR Newswire - Mon Mar 14, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.24 (unch), DMPI: 6.80 (-0.03), CDXC: 4.10 (-0.29), EKSO: 3.93 (-0.02)

Matinas BioPharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Thu Mar 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 5:00 p.m. PT in Dana Point, CA.

OTCQX And OTCQB Companies To Present At 2016 ROTH Conference
PR Newswire - Thu Mar 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the 28th Annual ROTH Conference, taking place March 13-16 at the Ritz-Carlton in Dana Point, CA. The ROTH Conference, hosted by ROTH Capital Partners, LLC, is one of the largest small-cap investment conferences in the U.S., featuring presentations by senior executives from hundreds of public and private companies in a wide variety of sectors.
VRAY: 3.24 (unch), DMPI: 6.80 (-0.03), CDXC: 4.10 (-0.29), EKSO: 3.93 (-0.02)

A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 123.16 (-0.61), CMRX: 4.54 (+0.07), MRK: 63.18 (-0.45), CDTX: 11.83 (-0.30), GSK: 44.30 (-0.09)

Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
GlobeNewswire - Mon Mar 07, 6:05AM CST
- MAT2501 (encochleated amikacin) previously designated a Qualified Infectious Disease Product by FDA -

Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
GlobeNewswire - Wed Feb 10, 7:05AM CST
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin B) and MAT2501 (Encochleated Amikacin) -

Matinas BioPharma to Present at Biotech Showcase(TM) on January 12, 2016
GlobeNewswire - Tue Jan 05, 6:01AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 2:30 p.m. PT in San Francisco, CA.

Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
GlobeNewswire - Mon Jan 04, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that on December 31, 2015, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead antibacterial development candidate, MAT2501.

Matinas BioPharma Holdings, Inc. - MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection
ACCESSWIRE - Wed Dec 23, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a series of blog posts on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Roelof Rongen and Chief Technology Officer, Dr. Raphael Mannino. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
GlobeNewswire - Thu Dec 17, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus.

Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
GlobeNewswire - Thu Nov 19, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8 Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.

Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 10, 6:35AM CST
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 -

Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
GlobeNewswire - Mon Oct 26, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/038,810 entitled, "Cochleate Compositions Directed Against Expression of Proteins."

Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
GlobeNewswire - Thu Oct 22, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25 to October 28 at The Cleveland Clinic, Cleveland, Ohio.

Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
GlobeNewswire - Wed Oct 14, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14 Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.

Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
GlobeNewswire - Sat Oct 10, 7:00AM CDT
- CATQ - Encochleated Atovaquone - Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation -

MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 20

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 314

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 23

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 13

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 12

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 287

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Meat Partners with Hard Rock Cafe for Burger Launch

Updated Category News Views 432

Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...

Continue Reading
ATEC Water Systems Welcomes Industry Leader Steve Green

Updated Category News Views 299

ATEC Water Systems welcomed Steve Green as their new Chief Commercial Officer back in 2024, shaking things up under the Cadiz, Inc. (NASDAQ: CDZI) umbrella. Traders watched closely; this wasn't just a run-of-the-mill hire but rather a strategic move aimed at revitalizing the company's trajectory in a crowded market. With Steve's extensive background in the water industry,...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 249

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading
Ascot Resources Explores Alternative TSXV Listing Options

Updated Category News Views 165

Ascot Resources Faces Delisting from TSX Ascot Resources Ltd., a Canadian mining company headquartered in Vancouver, is going through significant changes regarding its stock listings. Recently, the Continued Listing Committee of the Toronto Stock Exchange (TSX) informed Ascot that its common shares are set to be delisted at the market's close on a specified date. This...

Continue Reading
Albany International Corporation Faces Legal Scrutiny Amid Stockholder Concerns

Updated Category News Views 194

Introduction to the Investigation Albany International Corporation is currently experiencing legal scrutiny as concerns arise among stockholders regarding the company's financial performance. Recently, the law firm Bragar Eagel & Squire, P.C. has stepped in, urging investors who may have suffered losses in Albanian stocks to reach out for assistance. The firm seeks to...

Continue Reading